Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeligekimab early intervention in psoriasis vulgaris
ChiCTR2600131589Phase 4Not yet recruiting
- Sponsor
- Wuhan No.1 Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of xeligekimab in plaque psoriasis, sponsored by Wuhan No.1 Hospital. Primary endpoints: Proportion of patients with PASI <3 at Week 12 and Proportion of patients with PASI = 0 at Week 36. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
xeligekimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600131589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131589.